Australian medicinal cannabis company Bod (ASX: BDA) has seen sales of its MediCabilis product soar during August.
The company dispensed 329 MediCabilis prescriptions in August, representing an increase of 95 per cent from July 2019 when prescriptions totalled 169.
Further, prescriptions for August represent a 467 per cent increase on June 2019 when only 58 prescriptions were dispensed.
The company says the prescription uptake is being driven by its partners at Burleigh Heads Cannabis and its partner company Cannabis Doctors Australia.
Additionally a 12 month trial being undertaken by research partner Cannabis Access Clinics relating to the treatment of Post Traumatic Stress Disorder is also diving the increase.
The company says it has also observed consistent repeat prescriptions from patients and physicians.
"It is pleasing to observe the amount of repeat prescriptions that the company is receiving, as it clearly indicates the benefit it is providing to patients and product superiority," says Bod CEO Jo Patterson.
"Bod is confident that it will continue growth in prescription volumes as it progresses relationships with distributors in new markets and commences dispensing in the United Kingdom in the coming weeks."
Shares in Bod are up 6.59 per cent to $0.48 per share at 10.33am AEST.
Business News Australia
Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support